Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of $150,000,000 of its common stock and pre-funded warrants to purchase shares of common stock. The offering is subject to completion and is dated February 28, 2024. The pre-funded warrants will be sold at the public offering price per share of common stock minus $0.0001, multiplied by the number of shares subject to the warrant, with an exercise price of $0.0001 per share. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' On February 27, 2024, the last reported sale price of Arcutis' common stock was $10.63 per share. The offering is expected to provide 14,111,006 shares, assuming an assumed public offering price of $10.63 per share. The pre-funded warrants...Show More
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of $150,000,000 of its common stock and pre-funded warrants to purchase shares of common stock. The offering is subject to completion and is dated February 28, 2024. The pre-funded warrants will be sold at the public offering price per share of common stock minus $0.0001, multiplied by the number of shares subject to the warrant, with an exercise price of $0.0001 per share. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' On February 27, 2024, the last reported sale price of Arcutis' common stock was $10.63 per share. The offering is expected to provide 14,111,006 shares, assuming an assumed public offering price of $10.63 per share. The pre-funded warrants will not be listed on any market, and there is no expectation for a trading market to develop. The offering involves risks, including the absence of an established market for the pre-funded warrants and the potential dilution to existing shareholders. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are acting as underwriters for the offering.
处于商业阶段的生物制药公司Arcutis Biotherapeutics宣布发行1.5亿美元的普通股和预先注资的认股权证，以购买普通股。此次发行有待完成，日期为2024年2月28日。预先注资的认股权证将按普通股每股公开发行价格减去0.0001美元，乘以认股权证约束的股票数量出售，行使价为每股0.0001美元。普通股在纳斯达克全球精选市场上市，股票代码为 “ARQT”。2024年2月27日，Arcutis普通股最新公布的销售价格为每股10.63美元。假设公开发行价格为每股10.63美元，预计此次发行将提供14,111,006股股票。预先注资的认股权证不会在任何市场上市，交易市场预计不会发展。此次发行涉及风险，包括预先注资的认股权证缺乏既定市场，以及现有股东可能被稀释。摩根士丹利、道明考恩、古根海姆证券、瑞穗和Needham & Company担任此次发行的承销商。
处于商业阶段的生物制药公司Arcutis Biotherapeutics宣布发行1.5亿美元的普通股和预先注资的认股权证，以购买普通股。此次发行有待完成，日期为2024年2月28日。预先注资的认股权证将按普通股每股公开发行价格减去0.0001美元，乘以认股权证约束的股票数量出售，行使价为每股0.0001美元。普通股在纳斯达克全球精选市场上市，股票代码为 “ARQT”。2024年2月27日，Arcutis普通股最新公布的销售价格为每股10.63美元。假设公开发行价格为每股10.63美元，预计此次发行将提供14,111,006股股票。预先注资的认股权证不会在任何市场上市，交易市场预计不会发展。此次发行涉及风险，包括预先注资的认股权证缺乏既定市场，以及现有股东可能被稀释。摩根士丹利、道明考恩、古根海姆证券、瑞穗和Needham & Company担任此次发行的承销商。
有用
没用